Rheumatology
Conference Coverage
Long COVID risk not higher with rheumatic diseases
“The data demonstrate that rheumatic disease itself is not a risk factor for long COVID. However, patients with rheumatic diseases are at a higher...
Conference Coverage
Studies reveal nuances in efficacy, MACE risk between JAKi and TNFi
Three studies provide more data on risk for major adverse cardiovascular events with JAK inhibitors vs. TNF inhibitors, as well as their efficacy...
From the Journals
Gout linked to smaller brain volume, higher likelihood of neurodegenerative diseases
Patients with gout may have smaller brains with more iron, and they may be at increased risk for developing dementia and other neurodegenerative...
Latest News
Cell activity in psoriasis may predict disease severity and provide clues to comorbidities
Skin samples from patients with psoriasis showed more fibroblast clusters in the upper layers of the skin in moderate to severe cases.
Conference Coverage
Early axial spondyloarthritis diagnosis in referred patients remains stable in most
Patients who are diagnosed with axial spondyloarthritis after referral to a rheumatologist for chronic back pain most often keep that diagnosis,...
Conference Coverage
Investigational uricase-based gout drug meets primary endpoints in phase 3 trials
Two phase 3 trials of the once-monthly SEL-212 in refractory gout achieved and maintained serum uric acid < 6 mg/dL for ≥ 80% of the final...
Conference Coverage
EULAR systemic sclerosis recommendations now include immunosuppressants
The update to 2017 recommendations include targeted synthetic and biologic DMARDs for the first time.
Conference Coverage
URAT1 inhibitor shows ‘substantial’ uric acid reduction in phase 2 gout trial
The investigational drug, AR882, reduced serum uric acid to levels seen in people without hyperuricemia and gout.
Conference Coverage
Encouraging telitacicept results reported in phase 3 for lupus, phase 2 for Sjögren’s
Results of a phase 3 trial in Chinese patients with systemic lupus erythematosus showed a significantly greater response rate with telitacicept,...
Latest News
Scientists discover variants, therapy for disabling pansclerotic morphea
The JAK inhibitor ruxolitinib dramatically improved wound healing and rashes in patients with the very rare disorder.
Feature
Enthesitis, arthritis, tenosynovitis linked to dupilumab use for atopic dermatitis
Musculoskeletal symptoms identified in some patients treated with dupilumab for atopic dermatitis could help further understanding of how...